Vivakor Inc (VIVK)

$1.58

+0.03

(+1.94%)

Market is closed - opens 7 PM, 04 Jun 2024

Insights on Vivakor Inc

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 16.31M → 13.87M (in $), with an average decrease of 7.5% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 4 quarters, -1.84M → -3.84M (in $), with an average decrease of 29.7% per quarter

Performance

  • $1.53
    $1.65
    $1.58
    downward going graph

    2.97%

    Downside

    Day's Volatility :7.09%

    Upside

    4.24%

    downward going graph
  • $0.44
    $1.84
    $1.58
    downward going graph

    72.28%

    Downside

    52 Weeks Volatility :76.2%

    Upside

    14.13%

    downward going graph

Returns

PeriodVivakor IncIndex (Russel 2000)
3 Months
49.06%
0.0%
6 Months
58.17%
0.0%
1 Year
47.66%
0.0%
3 Years
-82.44%
-22.6%

Highlights

Market Capitalization
42.4M
Book Value
$0.6
Earnings Per Share (EPS)
-0.49
PEG Ratio
0.0
Profit Margin
-16.87%
Operating Margin TTM
-10.09%
Return On Assets TTM
-5.72%
Return On Equity TTM
-48.9%
Revenue TTM
59.8M
Revenue Per Share TTM
2.8
Quarterly Revenue Growth YOY
3.1%
Gross Profit TTM
37.8K
EBITDA
-2.7M
Diluted Eps TTM
-0.49
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Company Financials

FY20Y/Y Change
Revenue
1.5M
-
Net Income
-2.4M
↑ 9.14%
Net Profit Margin
-161.65%
-
FY21Y/Y Change
Revenue
1.1M
↓ 25.34%
Net Income
-5.5M
↑ 134.52%
Net Profit Margin
-507.74%
↓ 346.09%
FY22Y/Y Change
Revenue
28.1M
↑ 2482.37%
Net Income
-19.4M
↑ 251.74%
Net Profit Margin
-69.16%
↑ 438.58%
FY23Y/Y Change
Revenue
59.3M
↑ 111.06%
Net Income
-10.7M
↓ 44.76%
Net Profit Margin
-18.1%
↑ 51.06%
Q4 FY22Q/Q Change
Revenue
16.3M
↑ 38.89%
Net Income
-12.4M
↑ 681.78%
Net Profit Margin
-75.59%
↓ 62.16%
Q1 FY23Q/Q Change
Revenue
16.3M
↑ 0.0%
Net Income
-12.4M
↑ 0.0%
Net Profit Margin
-75.59%
↑ 0.0%
Q2 FY23Q/Q Change
Revenue
13.6M
↓ 16.83%
Net Income
-1.8M
↓ 85.07%
Net Profit Margin
-13.57%
↑ 62.02%
Q3 FY23Q/Q Change
Revenue
16.3M
↑ 20.03%
Net Income
-2.5M
↑ 36.47%
Net Profit Margin
-15.43%
↓ 1.86%
Q4 FY23Q/Q Change
Revenue
13.9M
↓ 14.96%
Net Income
-3.8M
↑ 52.62%
Net Profit Margin
-27.69%
↓ 12.26%
Q1 FY24Q/Q Change
Revenue
13.9M
↑ 0.0%
Net Income
-3.8M
↑ 0.0%
Net Profit Margin
-27.69%
↑ 0.0%
FY19Y/Y Change
Total Assets
39.6M
-
Total Liabilities
24.3M
-
FY20Y/Y Change
Total Assets
42.3M
↑ 6.81%
Total Liabilities
16.3M
↓ 33.03%
FY21Y/Y Change
Total Assets
47.3M
↑ 11.93%
Total Liabilities
20.2M
↑ 24.24%
FY22Y/Y Change
Total Assets
76.3M
↑ 61.25%
Total Liabilities
49.3M
↑ 144.07%
FY23Y/Y Change
Total Assets
71.2M
↓ 6.69%
Total Liabilities
54.0M
↑ 9.57%
Q4 FY22Q/Q Change
Total Assets
76.3M
↓ 19.47%
Total Liabilities
49.3M
↓ 13.74%
Q1 FY23Q/Q Change
Total Assets
76.3M
↑ 0.0%
Total Liabilities
49.3M
↑ 0.0%
Q2 FY23Q/Q Change
Total Assets
76.9M
↑ 0.75%
Total Liabilities
53.4M
↑ 8.36%
Q3 FY23Q/Q Change
Total Assets
76.1M
↓ 1.04%
Total Liabilities
52.2M
↓ 2.22%
Q4 FY23Q/Q Change
Total Assets
71.2M
↓ 6.41%
Total Liabilities
54.0M
↑ 3.42%
Q1 FY24Q/Q Change
Total Assets
71.2M
↑ 0.0%
Total Liabilities
54.0M
↑ 0.0%
FY18Y/Y Change
Operating Cash Flow
-268.0K
↓ 32.56%
Investing Cash Flow
-849.8K
↑ 125.27%
Financing Cash Flow
1.7M
↑ 1533.12%
FY19Y/Y Change
Operating Cash Flow
-195.5K
↓ 27.07%
Investing Cash Flow
-2.1M
↑ 141.81%
Financing Cash Flow
474.9K
↓ 72.7%
FY20Y/Y Change
Operating Cash Flow
-1.8M
↑ 797.13%
Investing Cash Flow
-1.2M
↓ 40.28%
Financing Cash Flow
2.8M
↑ 484.31%
FY21Y/Y Change
Operating Cash Flow
-2.9M
↑ 65.47%
Investing Cash Flow
-4.5M
↑ 267.88%
Financing Cash Flow
8.5M
↑ 206.72%
Q4 FY22Q/Q Change
Operating Cash Flow
-1.3M
↑ 98.1%
Investing Cash Flow
-883.8K
↑ 52.08%
Financing Cash Flow
1.1M
↑ 102.78%
Q1 FY23Q/Q Change
Operating Cash Flow
-690.3K
↓ 45.91%
Investing Cash Flow
-883.8K
↑ 0.0%
Financing Cash Flow
35.4K
↓ 96.79%
Q2 FY23Q/Q Change
Operating Cash Flow
-20.7K
↓ 97.01%
Investing Cash Flow
-1.1M
↑ 29.15%
Financing Cash Flow
1.1M
↑ 3012.19%

Technicals Summary

Sell

Neutral

Buy

Vivakor Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Vivakor Inc
Vivakor Inc
31.67%
58.17%
47.66%
-82.44%
-82.44%
Imperial Oil Ltd
Imperial Oil Ltd
-3.79%
16.63%
39.12%
95.3%
149.21%
Chevron Corporation
Chevron Corporation
-2.98%
8.69%
1.25%
45.19%
34.24%
Exxon Mobil Corp.
Exxon Mobil Corp.
-1.97%
11.73%
8.7%
86.25%
55.52%
Cenovus Energy Inc
Cenovus Energy Inc
-5.42%
13.99%
14.79%
107.64%
143.59%
Suncor Energy Inc.
Suncor Energy Inc.
-0.1%
19.21%
32.6%
52.37%
28.44%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Vivakor Inc
Vivakor Inc
NA
NA
0.0
0.0
-0.49
-0.06
NA
0.6
Imperial Oil Ltd
Imperial Oil Ltd
11.26
11.26
0.85
6.64
0.21
0.09
0.02
43.13
Chevron Corporation
Chevron Corporation
14.93
14.93
4.51
12.81
0.13
0.06
0.04
86.97
Exxon Mobil Corp.
Exxon Mobil Corp.
14.37
14.37
7.05
9.08
0.16
0.08
0.03
52.05
Cenovus Energy Inc
Cenovus Energy Inc
11.83
11.83
0.45
2.16
0.16
0.07
0.03
15.66
Suncor Energy Inc.
Suncor Energy Inc.
9.28
9.28
0.07
4.15
0.19
0.07
0.04
34.43
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Vivakor Inc
Vivakor Inc
NA
$42.4M
-82.44%
NA
-16.87%
Imperial Oil Ltd
Imperial Oil Ltd
Hold
$37.8B
149.21%
11.26
9.5%
Chevron Corporation
Chevron Corporation
Buy
$296.8B
34.24%
14.93
10.53%
Exxon Mobil Corp.
Exxon Mobil Corp.
Buy
$526.0B
55.52%
14.37
9.78%
Cenovus Energy Inc
Cenovus Energy Inc
Buy
$38.8B
143.59%
11.83
8.72%
Suncor Energy Inc.
Suncor Energy Inc.
Buy
$52.5B
28.44%
9.28
15.85%

Institutional Holdings

  • Smith Shellnut Wilson LLC

    11.48%
  • GREAT VALLEY ADVISOR GROUP, INC.

    0.26%
  • Geode Capital Management, LLC

    0.21%
  • Maryland Capital Advisors Inc

    0.09%
  • Atlantic Trust Group, LLC

    0.08%
  • Vanguard Group Inc

    0.04%

Company Information

vivakor inc is a company based out of 2590 holiday rd ste 100, coralville, iowa, united states.

Organization
Vivakor Inc
Employees
5
CEO
Mr. James H. Ballengee
Industry
Pharmaceuticals: Other

FAQs